AMT Stock Recent News

American Tower has outperformed on a YTD basis while raising their FY2024 guidance, thanks to the ongoing 5G upgrades and colocation growths. Even so, with over half of its sites already "upgraded with mid-band 5G," we may see FY2025 bring forth tougher YoY comparisons, as telecoms guide lower capex ahead. This is worsened by the prolonged densification process occurring only from 2026 onwards, along with the impact of the Sprint churn from Q4'24 onwards.

Besides Wall Street's top -and-bottom-line estimates for American Tower (AMT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

American Tower Corporation's international growth and asset sales have improved its relative position, but Crown Castle Inc. remains a strong buy due to its upside potential. Crown Castle has faced revenue and profit declines, largely due to Sprint cancellations, but remains a cash cow with potential asset sales as a growth catalyst. American Tower has shown consistent growth and better profit margins, making it a solid buy, though it is pricier than Crown Castle.

These five REITs ranked as the top performers over the past two decades.

American Tower remains overvalued, underperforming the S&P 500 by 40% since our last recommendation against investing in the company. The company's substantial debt, lofty valuation, and moderate growth prospects limit its potential for future shareholder returns. Rising competition in the datacenter sector and a high payout ratio could hinder American Tower's long-term dividend growth.

AMT to gain from increased investment by wireless carriers in 4G and 5G networks. Solid business fundamentals and strategic capital allocation are add-ons.

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with three dose-escalating cohorts assessing the safety, tolerability and exploratory signs of efficacy of AMT-162 in individuals with SOD1-ALS.

Economic growth could slowly pick up in the U.S. and globally, as inflationary pressures continue to ease, with the Fed joining the rate-cut “party,” which could lead to even stronger corporate earnings growth following this year's robust gains.

BOSTON--(BUSINESS WIRE)--American Tower Corporation (NYSE: AMT) announced today that the press announcement of its third quarter 2024 results is scheduled to be released to the news services at 7:00 a.m. ET on Tuesday, October 29, 2024. In addition, the Company has scheduled a conference call at 8:30 a.m. ET on October 29, 2024 to discuss its results. Conference call details are as follows: Call Date: Tuesday, October 29, 2024 Call Time: 8:30 a.m. ET     Call Dial in: (877) 692-8955 U.S./Canada.

Since July, markets have been volatile, and this volatility has provided plenty of opportunities for traders and those with a shorter-term investing time horizon to make some money.